drugset / Trial / NCT06656494
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
Timeline
- Start
- 2024-12-18
- Primary completion
- 2027-06
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-248 | Unknown | — | Oral |
| Background | Azacitidine | Other / unclassified | — | Subcutaneous |